Please assess the completion status of the following clinical trial:

Trial Title: Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of acute myeloid leukemia (AML), meeting one of the following criteria:~  * Relapsed or refractory disease (≥ 18 years of age)~ * Previously untreated disease (≥ 60 years of age)~* Secondary AML or therapy-related AML allowed~* No granulocytic sarcoma as the sole site of disease~* No active or relapsed CNS disease~* No advanced malignant solid tumors~* ECOG performance status 0-2~* Life expectancy \> 6 months (if patient has co-morbid illness)~* Total bilirubin \< 2.0 mg/dL~* AST and ALT \< 2.5 times upper limit of normal~* Creatinine \< 2.0 mg/dL~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~* Patients with HIV infection are eligible provided the following criteria are met:~  * No history of AIDS~ * Has a sufficiently high CD4 count (\> 400/mm³)~ * Has low HIV viral loads (\< 30,000 copies/mL plasma)~ * Does not require anti-HIV therapy~* No uncontrolled active infection~* No history of allergic reactions attributed to compounds of similar chemical or biological composition to decitabine or bortezomib that are not easily managed~* No hypersensitivity to boron or mannitol~* No concurrent uncontrolled illness including, but not limited to, any of the following:~  * Symptomatic congestive heart failure~ * Unstable or uncontrolled angina pectoris~ * Serious cardiac arrhythmia~ * Myocardial infarction within the past 6 months~ * New York Heart Association class III-IV heart failure~ * Severe uncontrolled ventricular arrhythmias~ * Acute ischemia or active conduction system abnormalities by ECG~* No serious medical or psychiatric illness or social situation that would preclude participation in this study~* No pre-existing neuropathy ≥ grade 2~* No other serious neurologic toxicity that would significantly increase the risk of complications from bortezomib therapy~* Recovered from prior therapy (toxicity \< grade 2)~* More than 14 days since prior investigational agents~* More than 2 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) or radiotherapy~* Prior decitabine or azacitidine for myelodysplastic syndromes (MDS) or AML allowed~* More than 6 months since prior decitabine, azacitidine, or bortezomib~* No concurrent palliative radiotherapy~* No other concurrent investigational agents~* No other concurrent direct anti-leukemia therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor therapy and chemotherapy) (Type: EXPERIMENTAL): Patients receive decitabine IV over 1 hour on days 1-5 or 1-10 and bortezomib IV on days 5 and 8 or days 5, 8, 12, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Once the maximum tolerated dose is determined, an additional 6 patients are treated at the recommended phase II dose.

Based on this trial design, predict the completion outcome and termination type (if applicable).